Management Change/Compensation (Form 8-K)

On April 15, 2026, upon the recommendation of the Nominating and Corporate Governance Committee of the Board of Directors (the "Board") of Envoy Medical, Inc. (the "Company"), the Board appointed Charles S. McKhann to serve as a Class I director, with an initial term expiring at the Company's 2027 annual meeting of stockholders. In connection with and effective as of his appointment to the Board, Mr. McKhann was also appointed to the Board's Compensation Committee (the "Compensation Committee"). Also in connection with his appointment, the size of the Board was increased from six members to seven members.

Mr. McKhann currently serves as a director of Exagen, Inc., a publicly traded diagnostics company, and as Executive Chairman at Distalmotion SA, a privately held surgical robotics company. Previously, Mr. McKhann served as the President, Chief Executive Officer, and a member of the board of directors of Silk Road Medical, Inc. ("Silk Road"), a medical device company, from November 2023 to September 2024, when Silk Road was purchased by Boston Scientific Corporation, and served as Chief Executive Officer, President and a member of the Board of Directors of Apollo Endosurgery, Inc. ("Apollo"), a medical device company, from March 2021 to April 4, 2023, when Apollo was purchased by Boston Scientific Corporation. From October 2017 to December 2018, Mr. McKhann served as Chief Commercial Officer at ROX Medical, Inc., a medical device company. From July 2016 to April 2017, he served as Chief Commercial Officer of Torax Medical, Inc., a medical device company acquired by Johnson & Johnson in April 2017. From January 2015 to July 2016, he served as Chief Commercial Officer of Intersect ENT, Inc., a medical device company. In addition, from September 2012 to March 2021, he served as Managing Director of Vernon Consulting, Inc. Mr. McKhann holds a B.A. in Political Sciences and an M.B.A. from Stanford University.

As of the date of his appointment to the Board, Mr. McKhann was awarded stock options to purchase 100,000 shares of the Company's Class A Common Stock, par value of $0.0001 per share, at a price of $0.72 per share, which stock option award will vest in 36 equally monthly installments. Mr. McKhann also entered into the Company's standard indemnification agreement for officers directors, the form of which was filed as Exhibit 10.21 to the Company's Current Report on Form 8-K, filed with the Securities and Exchange Commission on October 5, 2023 and is incorporated herein by reference.

There is no arrangement or understanding between Mr. McKhann and any other person pursuant to which Mr. McKhann was appointed as a director. Mr. McKhann is not a party to any transaction that would require disclosure under Item 404(a) of Regulation S-K. The Board has determined that Mr. McKhann is an independent director in accordance with the listing requirements of the Nasdaq Capital Market and the standards promulgated by the Securities and Exchange Commission, including enhanced independence criteria applicable to members of the Compensation Committee.